Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2006-05-02
2006-05-02
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C530S395000, C530S351000, C435S069500, C435S358000, C435S320100
Reexamination Certificate
active
07037491
ABSTRACT:
The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.
REFERENCES:
patent: 5756083 (1998-05-01), Elliott
patent: 6451554 (2002-09-01), Wood et al.
patent: 0 668 352 (1995-08-01), None
patent: WO 95/18858 (1995-07-01), None
patent: WO 95/21920 (1995-08-01), None
patent: WO 95/26746 (1995-10-01), None
patent: WO 96/17062 (1996-06-01), None
patent: WO 96/23888 (1996-08-01), None
patent: WO 96/25498 (1996-08-01), None
K. H. Pearce, Jr., et al., “Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites”, Journal of Biological Chemistry 272(2): 20595-20602, Aug. 15, 1997.
Hoffman et al., “Peptide, Disulfidc, and Glycosylation Mapping of Recombinant Human Thrombopietin Ser 1 to Arg 246”,Biochemistry, 1996, 35(47), 14849-14861 (Eng.) Columbus, OH, USA: Chemical Abstracts, vol. 126, No. 6, Feb. 10, 1997, p. 80, Abstract No. 70279s.
Park et al., “Identification of Funtionally Important Residues of Human Thrombopoietin”,The Journal of Biological Chemistry, vol. 273, No. 1, Jan. 2, 1998, pp. 256-261.
Sareneva et al., “Role of N-glycosylation in the Synthesis, Dimerization and Secretion of Human Interferon-γ”,Biochem. J., (1994) 303, pp. 831-840.
Asano et al., “The role of N-glycosylation in the targeting and stability of GLUTI glucose transporter”, FEBS 12589, vol. 324, No. 3, Jun. 1993, pp. 258-261.
Ahn Hyea Kyung
Chang Woo Ik
Chung Joo Young
Ju Sang Myoung
Koh Yeo Wook
Daewoong Pharmaceutical Co., Ltd.
Gates & Cooper LLP
Spector Lorraine
LandOfFree
Human thrombopoietin comprising glycosylation sited at... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human thrombopoietin comprising glycosylation sited at..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human thrombopoietin comprising glycosylation sited at... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3542187